Background: Small vessel size remains an independent predictor of restenosis and target lesion revascularization (TLR) even in the drug-eluting stent (DES) era. It is unknown whether second-generation DES improve outcomes in this lesion subset. This study aimed to compare the long-term clinical outcomes between everolimus-eluting stents (EES) and sirolimus-eluting stents (SES) in small coronary artery diseases. Methods: A total of 1160 patients treated with EES (nϭ475) or SES (nϭ685) in small coronary artery lesions (defined as size of the stent implanted of Յ2.75 mm) were retrospectively enrolled. Primary end point was ischemia-driven TLR at 12 months. Secondary end points were major adverse cardiovascular events (MACE; death, myocardial infarction, and target vessel revascularization) and stent thrombosis during 12-month follow-up. Results: Baseline characteristics were generally similar between stent groups, with the exception of a significantly greater prevalence of diabetes mellitus and systemic hypertension in the EES group. The EES group also had more type C lesions (47.7% vs. 24.5%, p Ͻ0.001). At 1 year, there was no significant difference in terms of TLR rate between EES and SES (5.4% vs. 5.2%, pϭ0.89). During follow-up, MACE occurred in 10.3% of EES-and 12.0% of SES-treated patients (pϭ0.38). Stent thrombosis was lower in the EES group (0.0% vs. 1.2%, pϭ0.024).
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Philip Urban Hôpital de la Tour, Geneva, Switzerland, 2 Triemli Hospital Zurich, Zürich, Switzerland, 3 Hopitaux Universaires de Geneve (HUG) , Geneva, Switzerland, 4 Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, 5 Bern University Hospital, Bern, Switzerland Background: Clinicians use data from different sources, such as randomized clinical trials (RCTs) and registries, to define optimal clinical practice. We assessed the impact of different study designs on 2-year adverse event rates in 2 studies of Biolimus A9-eluting stents (BES) -the LEADERS RCT and the e-BioMatrix PMS registry. Methods: The LEADERS (BES arm 857 pts) and the e-BioMatrix PMS (1102 pts) enrolled similar patients but had several design differences including patient selection, degree of monitoring, protocol-driven measurements and event definitions. We expected lower event rates in the e-BioMatrix PMS consistent with a PP analysis, vs. ITT in LEADERS. To clarify how the differences in designs affected event rates during different FU periods, we performed a 2-day landmark analysis to focus on out-of-hospital events. Results: Baselines were similar between LEADERS and e-BioMatrix PMS e.g. diabetes: 26% vs 24% (pϭ0.32), ACS: 55% vs. 53% (pϭ0.41), STEMI: 16% vs 19% (pϭ0.05)), although LEADERS had higher prior PCI (36% vs 25% (pϽ0.001)) and prior MI (32% vs 21% (pϽ0.001)). At 2 years, the e-BioMatrix PMS showed similar rates of cardiac death (CD) (2.4% vs 3.2%), Q-wave MI (0.8% vs 0.5%) and ci-TVR (6.4% vs 7.7%, p ϭ 0.26) vs. LEADERS, but lower rates of all MI (3.1% vs. 6.4%, pϽ0.001). MACE rates were 9.5% and 13% (pϽ0.01).Although e-BioMatrix showed a lower early definite ST vs LEADERS (0.5% vs 1.6%, pϽ0.05), the late and very late ST were similar. The 2-day landmark showed that the lower adverse event rates in the e-BioMatrix PMS compared to LEADERS were mainly driven by differences in the first 2 days. There were no significant differences between 3 days and 2 years in MACE, CD, MI, ci-TVR and definite ST. Conclusions: We found a large degree of reproducibility for event rates Ͼ2 days. Lower in-hospital rates in e-BioMatrix PMS are likely due to design differences including PP vs. ITT analysis, mandatory ECG and biomarker determinations required post-procedure, and lower biomarker thresholds for MI in LEADERS. This study emphasizes that design criteria could impact on study results, even when the quality of data collection, monitoring and FU of a registry is comparable with those of a RCT.
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Percutaneous Background: Drug-eluting stents (DES) are frequently used to treat complex patient and lesion subsets with good efficacy and safety. This study aimed to compare the in-hospital and 1-year clinical outcomes of patients with complex clinical and angiographic characteristics treated with 1st-versus 2nd-generation DES. Methods: The study included 5190 consecutive patients with Ն1 of the following characteristics: Ejection fraction (EF) Ͻ30%, chronic renal insufficiency (CRI), cardiogenic shock, bifurcation, unprotected left main, totally occluded, ACC/AHA Type C lesion, bypass graft, in-stent restenosis (ISR), presence of thrombus, Ͼ1 lesion treated, and stent implantation length Ն 28 mm. Patients presenting with ST-segment elevation myocardial infarction (STEMI) were excluded. Clinical outcomes of patients treated with 1st-generation DES (Cypher/Taxus) (nϭ3834) were compared to those treated with 2nd-generation DES (Promux/Xience) (nϭ1356). Results: Baseline characteristics, non-STEMI (15.3% overall) at presentation, and CRI (15.1% overall) were similar in both groups. 2nd-generation DES were used more in insulin-treated diabetics (14.7 vs. 11.7%, pϭ0.005), type C lesions (50.4 vs. 22.7 %, pϭϽ0.001), and distal lesions (27.2 vs. 12.8 %, pϭϽ0.001). 1st-generation DES were used more in cardiogenic shock (1.7 vs. 0.6%, pϭ0.003), ISR (4.7 vs. 2.8%, p Ͻ0.001), vein graft (6.0 vs. 4.5%, pϭ0.011) and ostial lesions (4.9 vs. 2.4%, p Ͻ0.001). Angiographic success was similar at 99.1% overall. Major in-hospital complications and 1-year cumulative major adverse cardiac events were low overall, but were significantly higher in the 1st-generation compared to 2nd-generation DES group. (Table) . 
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